29 September 2020 : Clinical Research
Use of the Gout Impact Scale to Evaluate Quality of Life in Chinese Subjects with Gout: A Cross-Sectional Study
Peidan Yang12CDE, Zhixin Chen23CDE, Yimin Talia Chen4EF, Minying Liu1BF, Mingying Zhang1BF, Xiangwei Yang1BF, Changsong Lin1ADF, Qiang Xu1ABDEFG*DOI: 10.12659/MSM.925593
Med Sci Monit 2020; 26:e925593
Table 1 Baseline characteristics of gout patients.
| Variable | N=169 |
|---|---|
| Age (years), median (IQR) | 43 (34–53.5) |
| Gender, Male, n (%) | 149 (88.2) |
| BMI(kg/m), median (IQR) | 25.78 (23.55–28.06) |
| Education level, n (%) | |
| Primary education | 12 (7.1) |
| Junior high school | 35 (20.7) |
| Junior college | 39 (23.1) |
| Senior high school | 39 (23.1) |
| Bachelor degree or above | 44 (26.0) |
| Income/month (RMB), n (%) | |
| ≤3000 | 38 (22.5) |
| 3001~5000 | 52 (30.8) |
| 5001–10000 | 42 (24.9) |
| 10001–20000 | 23 (13.6) |
| ≥20000 yuan | 14 (8.3) |
| Sources of medical expenses (RMB), n (%) | |
| Self-paying | 56 (33.1) |
| Reimbursable items | 113 (66.9) |
| Smoking | 60 (35.5) |
| Alcohol drinking | 62 (36.7) |
| Disease duration (month), median (IQR) | 36 (12–71) |
| A family history of gout, n (%) | 47 (27.8) |
| During an attack (half a year), n (%) | 85 (50.3) |
| Number of attacks at half a year, n (%) | |
| 0 | 30 (17.8) |
| 1–2 | 66 (39.1) |
| 3–5 | 43 (25.4) |
| 6–10 | 21 (12.4) |
| >10 | 9 (5.3) |
| Baseline ULT use n (%) | |
| Allopurinol | 33 (19.5) |
| Febuxostat | 43 (25.4) |
| Benzbromarone | 22 (13.0) |
| GIS, median(IQR) | |
| Gout concern overall | 87.5 (75–100) |
| Gout medication side effects | 75 (62.5–100) |
| Unmet gout treatment | 41.67 (33.33–50) |
| Well-being during attack | 43.18 (30.68–54.55) |
| Gout concern during attack | 75 (68.75–93.75) |
| Data are n (%), median (IQR), or mean(S.D). GIS: 0 to 100; higher score indicates more serious symptoms of gout or terrible quality of life. GIS – Gout Impact Scale; IBM – body mass index; IQR – interquartile range; S.D. – standard deviation; ULT – uric acid lowering therapy. | |